ASSET PURCHASE AGREEMENT BY AND BETWEEN CIDARA THERAPEUTICS, INC. AND NAPP PHARMACEUTICAL GROUP LIMITED DATED AS OF 24 APRIL, 2024Asset Purchase Agreement • April 29th, 2024 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This ASSET PURCHASE AGREEMENT (this “Agreement”), dated as of 24 April, 2024, is entered into by and between CIDARA THERAPEUTICS, INC., a Delaware corporation (the “Seller”), and NAPP PHARMACEUTICAL GROUP LIMITED, a company incorporated under the laws of England with company registration number 884285 (the “Buyer”). Capitalized terms used in this Agreement, including the Recitals, have the respective meanings set forth in Article 1.
FIRST AMENDMENT TO LICENSE AGREEMENTLicense Agreement • April 29th, 2024 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances)
This First Amendment to the License Agreement (“Amendment”) is entered into and effective as of April 23, 2024 (the “Amendment Date”), by and between Melinta Therapeutics, LLC, a Delaware limited liability company, having a place of business at 389 Interpace Parkway, Suite 450, Parsippany, NJ 07054 (together with its subsidiaries, “Melinta”), and Cidara Therapeutics, Inc., a corporation organized under the laws of the State of Delaware, USA, having its principal offices at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121, USA (“Cidara”).
Assignment and Novation AgreementAssignment and Novation Agreement • April 29th, 2024 • Cidara Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
This Assignment and Novation agreement (“Agreement”) dated as of April 24, 2024 (the “Effective Date”), is entered into by and among CIDARA THERAPEUTICS, INC., a corporation organized under the laws of the State of Delaware, USA, having its principal offices at 6310 Nancy Ridge Drive, Suite 101, San Diego, California 92121, USA (the “Transferor”), NAPP PHARMACEUTICAL GROUP LIMITED, a company incorporated under the laws of England, having its principal offices at Unit 191 Cambridge Science Park, Milton Road, Cambridge, England, CB4 0AB (the “Transferee”), MUNDIPHARMA MEDICAL COMPANY, a general exempted partnership established and existing under the laws of Bermuda, having its principal offices at Par La Ville Place, 14 Par La Ville Road, Hamilton HM08, Bermuda (“MMCO”), and MUNDIPHARMA MEDICAL COMPANY LIMITED, a company incorporated under the laws of England, having its principal offices at Unit 196 Cambridge Science Park, Milton Road, Cambridge, England, CB4 0AB (“MMCL”, and together w
